Over the last year, covered entities participating in the 340B Drug Pricing Program (340B Program) have anxiously monitored a flurry of litigation that could determine the scope of the 340B Program. The litigation and related enforcement actions were prompted by multiple drug manufacturers which, beginning in 2020, asserted that discounted 340B pricing would no longer
More Posts
HHS Extends Timeline for Spending Provider Relief Fund
Congress Requires New Medicaid Payment Reporting
Congress Overrides HHS Guidance on Use of Provider Relief Funds
New HHS Board Will Hear 340B Drug Pricing Disputes
COVID-19: Provider Relief Fund General Distribution – Phase 3
COVID-19: HHS Publishes Long-awaited Reporting Requirements for Provider Relief Fund Recipients
COVID-19: Take Two (for some) on Additional DHHS Provider Relief Funding
Webinar: COVID-19 Provider Relief Funding – Use of Funds, Attestations, and Risk Analysis
COVID-19: Understanding HHS’s Plans To Disperse Provider Relief Funds Authorized By The CARES Act
Subscribe: Subscribe via RSS
Blogs
Firm/Org